GlassScriptPhysician profile
Stacey Rock
NPI 1578180162
$4,673.33
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $1,251 · 2023: $1,293 · 2024: $879 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,193.66 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,129.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $385.20 | 2022-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $357.80 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $286.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $282.39 | 2021-2025 | |
| Amgen INC. | $135.24 | 2021-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $121.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $111.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $88.13 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceuticals, INC. | $84.98 | 2021 | |
| Astellas Pharma US INC | $78.11 | 2022-2024 | Veozah |
| Glaxosmithkline, LLC. | $65.39 | 2022-2023 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $60.04 | 2021-2024 | Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $58.80 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $44.31 | 2023 | Quviviq |
| Amarin Pharma, INC. | $41.39 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $31.90 | 2024 | Evkeeza |
| Esperion Therapeutics, INC. | $23.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.05 | 2024 | Rexulti |
| Antares Pharma, INC. | $17.99 | 2024 | Xyosted |
| Currax Pharmaceuticals LLC | $16.49 | 2024 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.01 | 2025 | NP Thyroid 60 |
| Eisai INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Rock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.